Here's Why We're Not At All Concerned With GH Research's (NASDAQ:GHRS) Cash Burn Situation [Yahoo! Finance]
GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
What Does GH Research PLC (GHRS)'s Clinical Progress Updates Say? [Yahoo! Finance]
GH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3 [Seeking Alpha]
GH Research (GHRS) was given a new $34.00 price target by Guggenheim.